PBI89 PHARMACOUTILIZATION OF BIOLOGICAL DRUGS IN PATIENTS AFFECTED BY PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS IN AN ITALIAN REAL-WORLD SETTING.

Authors :: Colombo, D.
Zagni, E.
Perrone, V.
Sangiorgi, D.
Andretta, M.
De Sarro, G.
Nava, E.
Degli Esposti, L.
Source :: Value in Health. 2019 Supplement 3, Vol. 22, pS434-S434. 1p.
Publication Year :: 2019
Abstract: The main objective was to determine the monthly average dose for biologic drugs used for psoriasis (PSO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). For adalimumab, PSO-patients had a monthly average dose of 69, PsA-patients 73 and AS-patients 70. [Extracted from the article]

Subjects :: *PSORIATIC arthritis
*ANKYLOSING spondylitis
*PSORIASIS
*ADALIMUMAB
*DRUGS

Full Text Access

Tools